Friday, October 2, 2020
News
NEWS HOME
»
PRN INDIA
Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine
  SocialTwist Tell-a-Friend  
   

Company working  to ensure broad global access to COVID-19 vaccine candidate, following approval from regulators

NEW BRUNSWICK,  New Jersey, Aug. 5, 2020 /PRNewswire/ --  Johnson & Johnson (NYSE: JNJ) (the Company) today announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing and delivery in the U.S. of 100 million doses of Janssen's SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use in the United States following approval or Emergency Use Authorization by the U.S. Food and Drug Administration (FDA).

The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, in collaboration with the U.S. Department of Defense, is committing over $1 billion for this agreement. The vaccine will be provided at a global not-for-profit basis for emergency pandemic use. The U.S. government may also purchase an additional 200 million doses of Ad26.COV2.S under a subsequent agreement.

"Johnson & Johnson's global team of experts has worked tirelessly alongside BARDA and scientific partners to pursue a SARS-CoV-2 vaccine that can help to stop the spread of COVID-19. We greatly appreciate the U.S. government's confidence in, and support for, our R&D platform and efforts and the scalability of our vaccine technology. We are scaling up production in the U.S. and worldwide to deliver a SARS-CoV-2 vaccine for emergency use," said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson.

Johnson & Johnson's efforts to develop a SARS-CoV-2 vaccine have been undertaken pursuant to an ongoing research and development collaboration with BARDA and under the oversight of the FDA. Based on the positive preclinical data recently published in the peer reviewed journal Nature, the Phase 1/2a first-in-human clinical trial of the vaccine candidate, Ad26.COV2.S, is underway in healthy volunteers in the United States and Belgium.

The Company is evaluating one- and two-dose regimens, in its clinical program and working diligently to ensure broad, global access to the vaccine following approval or authorization by regulators. Johnson & Johnson aims to meet its goal to supply more than one billion doses globally through the course of 2021, provided the vaccine is safe and effective.

Johnson & Johnson's SARS-CoV-2 vaccine program leverages Janssen's AdVac ® technology. The same technology was used to develop Janssen's European Commission-approved Ebola vaccine and construct its HIV, RSV and Zika vaccine candidates. More than 90,000 individuals have been vaccinated to date using the Janssen AdVac ®-based platform.

About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. Learn more at  www.jnj.com. Follow us at  @JNJNews.

About the Janssen Pharmaceutical Companies
At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at  www.janssen.com. Follow us at  @JanssenGlobal.

Notice to Investors Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding development  of potential preventive and treatment regimens for COVID-19. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Pharmaceuticals Inc., and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

(PRNewsfoto/Johnson & Johnson)

Logo - https://mma.prnewswire.com/media/403394/Johnson_and_Johnson_Logo.jpg

More News by PR Newswire India

PolyU launches the first dedicated interdisciplinary master programme in medical physics to nurture future clinical and academic talents in the field

New NCCN Resource for Understanding Childhood Leukemia

104 episodes of animated series Dabangg from Cosmos-Maya to launch on Disney+ Hotstar VIP

Blue Blocks Montessori School files a record 5 patents for student Inventions in Drones

Nuvoco launches 'Artiste Signature Collection' in association with Gauri Khan Designs and International Designs

Resilient Cities Network focuses its new city-led entity on strengthening cities capacity to recover from COVID-19 and build a safe and equitable world

Frost & Sullivan Recognizes Xenex with 2020 Global Company of the Year Award; LightStrike Robots Dominate Healthcare Room Disinfection Devices Market

Three corporate stalwarts; Sanjay Kaul ex Country Head Apple India, Ajay Kaul ex CEO - Jubilant Food Works, India, Mukesh Kachroo ex CTO - Gain Capital, USA set to launch a Digital Platform to Preserve and Promote Kashmiri Pandit Culture

Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate

QS Business Masters Rankings 2021 - Revealed: the specializations most in-demand among employers around the world

OrbusNeich® Announces China Approval for COMBO® Coronary Stent

Former HSBC Group COO Andy Maguire joins Thought Machine as new Chair

FDI World Dental Federation and Smile Train: Children with clefts are at high risk for tooth decay, gum disease and other serious oral health concerns

LONGi wins first order to supply 103 MW of Hi-MO 5 modules for TBEA's production base in Xinjiang

Clarivate Reveals 2020 Citation Laureates - Annual List of Researchers of Nobel Class

iHerb Meeting Increased Worldwide Demand for Vitamin D and C

"Jim Murray's Whisky Bible 2021" Matsui Whisky awarded "Best Japanese Single Cask Of The Year 2021"

Next-generation Wireless Business Support Systems to Enhance Digital Efficiency for Communication Service Providers

Lebenor Launches Halcove Touch Free Buttons to make Elevators safe to travel

Annova Solutions Helping Client's Journey with Dedicated Teams Working on Industry-specific Labels

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
NCW seeks action taken report from Chhat...
J&K police stops youth from joining terr...
Indian Army to get new communication net...
BJP Central Election Committee to meet o...
West Bengal BJP invites Shah, Nadda to v...
Longitudinal ageing study will provide e...
More...    
 
 Top Stories
US Senate panel votes to subpoena F... 
Indian Army to procure 10 lakh hand... 
'Bekhayali' duo Sachet-Parampara to... 
NASA launches $5mn competition to f... 
BJP, Cong play second fiddle to all... 
KXIP win toss, choose to bowl again... 
Himesh Reshammiya gives Bollywood o... 
Abu Dhabi's Mubadala to invest over...